TG Therapeutics To Host Conference Call On Second Quarter 20...| MENAFN.COM

Friday, 12 August 2022 02:22 GMT

TG Therapeutics To Host Conference Call On Second Quarter 2022 Financial Results And Business Update


(MENAFN- GlobeNewsWire - Nasdaq)

NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, August 8, 2022 at 8:30 AM ET to discuss results for the second quarter of 2022. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at . An audio recording of the conference call will also be available for replay at , for a period of 30 days after the call.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT TG THERAPEUTICS
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). For more information, visit  , and follow us on Twitter @TGTherapeutics and Linkedin .

CONTACT:

Investor Relations
Email:
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email:
Telephone: 1.877.575.TGTX (8489), Option 6




MENAFN05082022004107003653ID1104652089


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.